A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 165-171

  Fumoleau, P ^a,i   Chevallier, B ^b   Kerbrat, P ^c   Krakowski, Y ^d   Misset, J L ^e   Maugard Louboutin, C ^a   Dieras, V ^f   Azli, N ^g   Bougon, N ^g   Riva, A ^g   Roche, H ^h  

^a Ctr Regionale Lutte Contre le C   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE ALEXIS VAUTRIN   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f INSTITUT CURIE   (France)

^g SANOFI   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ Ctr Regionale Lutte Contre le C   (France)

Author keywords

Anticancer chemotherapy; Breast cancer locally advanced; Breast cancer metastatic; Docetaxel; Taxoids

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DOCETAXEL;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; FEMALE; FLUID RETENTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAIL INFECTION; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; VOMITING;

EID: 13344284659     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010544     Document Type: Article

References (27)

1. Jensen OM, Esteve J, Moller H et al. Cancer in the European Community and its member states. Eur J Cancer 1993; 26: 1167-256.
2. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In DeVita T Jr, Hellman S, Rosenberg SA (eds): Cancer: Principle and Practice of Oncology, 4th edition. Philadelphia: JB Lippincott Co. 1993; 1264-332.
3. Leonard RCF, Rodger A, Dixon JM. Metastatic breast cancer. BMJ 1994; 309: 1501-4.
4. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 (Suppl 4): 17-28.
5. Rowinsky EK, Cazenae LA, Donehower RC. Taxol: A novel investigational antineoplastic agent. J Natl Cancer Inst 1990; 82: 1247-59.
6. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
7. Reichman BS, Seidman AD, Crown JPA et al. Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
8. Bissery M-C, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumour activity of Taxotere (RP 56979, NSC 628503), a taxol analogue. Cancer Res 1991; 51: 4845-52.
9. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91.
10. Hanauske A-R, Degen D, Helsenbeck SG et al. Effect of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 1992; 3: 121-4.
11. Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22.
12. Dieras V, Fumoleau P, Chevallier B et al. Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere (docetaxel) as first line chemotherapy for advanced breast cancer. Proc Am Soc Clin Oncol 1994; 13: 78 (Abstr 115).
13. Data on file, Rhône-Poulenc Rorer.
14. Fleming T. One-sample multiple testing procedure for phase Ii clinical trials. Biometrics 1982; 38: 143-51.
15. Simon R. Optimal two-stage design for phase Ii clinical trials. Controlled Clin Trials 1989; 10: 1-10.
16. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105: 429-35.
17. Henderson IC. Chemotherapy for metastatic disease. In Harris JR, Hellman S, Henderson IC et al. (eds): Breast Disease, 2nd edition. Philadelphia: JB Lippincott 1991; 604-65.
18. Aisner J, Weinberg V, Perloff M et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFP v CMF each +/- MER) for metastatic carcinoma of the breast. A CALGB study. Cancer and leukemia Group B. J Clin Oncol 1987; 5: 1523-33.
19. Brinckner H, Rose C, von der Maase H, Dombernowsky P. A randomized study of CAF + TAM (tamoxifen) versus CMF + TAM in metastatic breast cancer. Proc Am Soc Clin Oncol 1984; 3: 113.
20. Bull JM, Tormey DC, Shou-Hua L et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649-57.
21. Spielmann M, Dorval T, Turpin F et al. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994; 12: 1764-70.
22. Tormey DC, Weinberg VE, Leone LA et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A cancer and leukemia study group B study. Am J Clin Oncol 1984; 7: 231-9.
23. French Epirubicin Study Group. A propsective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 1988; 4: 679-88.
24. Italian Multicenter Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs. fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 1988; 6: 976-82.
25. Seidman AD, Barrett S, Hudis et al. Three hour taxol infusion as initial (I) and as salvage (S) chemotherapy of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1994; 13: 66 (Abstr 65).
26. Schrijvers D, Wanders J, Dirix L et al. Coping with toxicities of docctaxel (Taxotere™). Ann Oncol 1993; 4: 610-1.
27. Valero V, Ravdin PM, Walters R et al. Taxotere™ (docetaxel) in the treatment of anthracycline/anthracenedione-refractory metastatic breast cancer (ARMBC): Combined results of 2 USA. phase II studies. Ann Oncol 1994; 5 (Suppl 8): 33 (Abstr).